<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23795">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797015</url>
  </required_header>
  <id_info>
    <org_study_id>RPC01-1001</org_study_id>
    <nct_id>NCT02797015</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS</brief_title>
  <official_title>A Phase 1, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics and Pharmacodynamics of RPC1063 in Patients With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn about the pharmacokinetics and pharmacodynamics of
      RPC1063 in RMS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to characterize the full pharmacokinetic and pharmacodynamics
      profiles of RPC1063 in patients with relapsing multiple sclerosis (RMS) following
      multiple-dose administration of the two different dosing regimens that are being evaluated
      in the Phase 3 RMS studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>24 hours after the last RPC1063 dose on Day 85</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Approximately 3 months</time_frame>
    <description>Area under the plasma concentration-time curve (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 28 days after the last RPC1063 dose</time_frame>
    <description>Number of participants with treatment-emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDSS (Expanded Disability Status Scale)</measure>
    <time_frame>Up to the last RPC1036 dose on Day 85</time_frame>
    <description>Changes from baseline in EDSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic response measured in change from baseline in Absolute Lymphocyte Count</measure>
    <time_frame>Up to 28 days after the last RPC1063 dose</time_frame>
    <description>Pharmacodynamic response measured in change from baseline in Absolute Lymphocyte Count (absolute and %)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1 mg RPC1063</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg RPC1063 oral capsule daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg RPC1063</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg RPC1063 oral capsule daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPC1063</intervention_name>
    <description>Oral capsule daily</description>
    <arm_group_label>1 mg RPC1063</arm_group_label>
    <arm_group_label>0.5 mg RPC1063</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  MS, as diagnosed by the revised 2010 McDonald criteria

          -  Exhibits a relapsing clinical course consistent with RMS and history of brain MRI
             lesions consistent with MS

          -  Expanded disability status scale (EDSS) score between 0 and 6.0

        Key Exclusion Criteria:

          -  Primary progressive MS

          -  Clinically relevant cardiovascular conditions or other relevant diseases that could
             impact the implementation or interpretation of the trial, or put the patient at risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Palmer McCloskey</last_name>
    <phone>858 9255508</phone>
    <email>pamccloskey@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site no. 122</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no. 120</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no. 143</name>
      <address>
        <city>Raliegh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no. 107</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no. 144</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 28, 2016</lastchanged_date>
  <firstreceived_date>May 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MS</keyword>
  <keyword>RMS</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Relapsing Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
